Ultragenyx Pharmaceutical (RARE) Q1 2024 Earnings
RARE·Reported May 2, 2024·After market close
Ultragenyx Pharmaceutical reported Q1 2024 revenue of $108.8M, missed analyst consensus of $116.0M by $7.2M. Diluted EPS came in at $-2.03, missed the $-1.72 consensus by $0.31.
Revenue
$108.8Mmissed by $7.2M
Consensus: $116.0MDiluted EPS
$-2.03missed by $0.31
Consensus: $-1.72
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about Ultragenyx Pharmaceutical's Q1 2024 earnings report.
Ultragenyx Pharmaceutical (RARE) reported Q1 2024 earnings on May 2, 2024 after market close.
Ultragenyx Pharmaceutical reported revenue of $108.8M and diluted EPS of $-2.03 for Q1 2024.
Revenue missed the consensus estimate of $116.0M by $7.2M. EPS missed the consensus estimate of $-1.72 by $0.31.
You can read the 10-Q periodic report (0000950170-24-052346) directly on SEC EDGAR. The filing index links above go to sec.gov.